Sign in
Taking peopleNo phase

Cardiac Autonomic and Anxiety Regulation Via Closed-loop nEurofeedback in Recurrent Pregnancy Loss

Key facts

Who runs it
Shenyang Medical College
Where
China2 sites in 1 countryChoose a country to see its sites
Trial code
Status
Recruiting
People taking part
62 people, planned
Started
29 Dec 2025
Planned end
30 Oct 2026
Type of study
Interventional, 2 groupsOne group gets an existing treatment, for comparison.
Treatments tested
  • Right DLPFC fNIRS-BCI closed-loop neurofeedback (real feedback)
  • Right DLPFC fNIRS-BCI neurofeedback (sham feedback)
Record updated
24 April 2026

Who can take part

Age
18 years to 45 years
Sex
Women only
Healthy volunteers
Cannot take part

The registry criteria, word for word

Show all 10 criteriaShow less

Who can take part

  • (i) Women aged 18-45 years, right-handed
  • (ii) Diagnosis of recurrent pregnancy loss (RPL), defined as ≥2 consecutive spontaneous pregnancy losses occurring before 28 weeks of gestation
  • (iii) Not currently pregnant, or currently in a missed miscarriage state
  • (iv) Meet DSM-5 diagnostic criteria for an anxiety disorder, with at least moderate severity, defined as Clinical Global Impression-Severity (CGI-S) ≥4
  • (v) Hamilton Anxiety Rating Scale (HAMA) ≥16, with 17-item Hamilton Depression Rating Scale (HAMD-17) <17, to ensure anxiety is the predominant affective disturbance

Who cannot take part

  • (v) Use of any oral antidepressant, anxiolytic, or antipsychotic medication within the past 4 weeks, or fluoxetine within the past 6 weeks, or any long-acting injectable antipsychotic within the past 3 months
  • (ii) Clinically important comorbid organic diseases, including but not limited to hyperthyroidism, history of atrial fibrillation, sinus bradycardia, major neurological disorders, cerebrovascular disease, or severe pulmonary disease
  • (iii) Significant suicide risk, judged by psychiatric assessment to be unsuitable for study participation
  • (iv) Other severe psychiatric disorders, including substance use disorder, schizophrenia, delusional disorder, unspecified psychotic disorder, bipolar disorder, or delirium
  • (i) Markedly unstable blood pressure (systolic BP >180 mmHg or <90 mmHg)

The main criteria, as questions

These questions come from the eligibility criteria published for this trial. They help you read the criteria and prepare for a talk with your doctor or the study team. We do not tell you a result. Only the study team can say whether you can take part.

  • Are you between 18 and 45 years old?

This trial is currently available in China.

It has sites in one country. Choose a country to see its sites.

About the trial

What the trial wants to find out

The goal of this clinical trial is to learn whether right dorsolateral prefrontal cortex (right DLPFC)-targeted fNIRS-BCI online closed-loop neurofeedback, delivered with slow-wave acoustic cueing, can reduce anxiety symptoms and improve cardiac autonomic regulation in women with recurrent pregnancy loss (RPL) and comorbid anxiety (women aged 18-45 years, right-handed, currently not pregnant or in a missed miscarriage state).

Read full original descriptionShow less

The main questions it aims to answer are:

Does real neurofeedback increase the proportion of participants who achieve an anxiety treatment response (defined as ≥50% reduction in Hamilton Anxiety Rating Scale [HAMA] total score from baseline) compared with sham feedback, at end of treatment and at 3-month follow-up? Is the intervention safe and well tolerated, as reflected by between-group differences in adverse events during the training period? Do brain and autonomic measures show between-group differences during the first formal session, including right DLPFC HbO downregulation, interhemispheric DLPFC synchronisation, heart rate (HR), and heart rate variability (HRV) indices? Researchers will compare real right DLPFC neurofeedback to sham feedback (identical procedures and displays but weakened coupling to real-time neural activity) to see if real neurofeedback improves anxiety outcomes and brain-heart autonomic regulation.

Participants will:

Complete screening, baseline clinical assessments, and physical examination Be randomly assigned (1:1) to real neurofeedback or sham feedback Complete 3 days of adaptation training followed by 3 weeks of training (15 sessions; one weekday session per day; ~20 minutes each) using a block design with slow-wave acoustic cueing (1 Hz amplitude-modulated tone; 20 s rest + 40 s cueing per block; 20 blocks/session) Undergo fNIRS recording in all sessions, with ECG recorded in session 1 only (for HR/HRV analyses) Receive matched, guideline-informed cognitive-behavioural therapy (CBT) during the intervention period Complete anxiety-related assessments at baseline, ~1 hour after the final session, and 3 months after treatment, with adverse events monitored throughout the intervention period

The 2 groups in the trial

  • a real-feedback intervention groupExisting treatment, for comparison

    Participants will receive right DLPFC targeted fNIRS-BCI online closed-loop neurofeedback delivered with slow-wave acoustic cueing. Training includes a 3-day adaptation phase followed by 3 weeks of formal training (15 weekday visits; about 20 minutes per visit) using a block design (20 blocks per visit; 60 seconds per block: 20 seconds rest + 40 seconds slow-wave acoustic cueing with a 1 Hz sinusoidally amplitude-modulated pure tone at about 60 dB). During each cueing period, real-time right DLPFC activation estimated from fNIRS is displayed as a visual activation bar; participants apply volitional strategies to downregulate activity below a concealed threshold line (T = -3.3; approximating p = 0.001). fNIRS is recorded in all visits; ECG is recorded on the first formal training day only for HR/HRV measures.

    Treatment: Right DLPFC fNIRS-BCI closed-loop neurofeedback (real feedback)

  • a sham-feedback control groupSham treatment, for comparison

    Participants will receive sham fNIRS-BCI neurofeedback targeting the right DLPFC under procedures identical in appearance and schedule to the real-feedback arm, including the same slow-wave acoustic cueing and block design (20 blocks per visit; 60 seconds per block: 20 seconds rest + 40 seconds cueing with a 1 Hz sinusoidally amplitude-modulated pure tone at about 60 dB). fNIRS is recorded in all visits; ECG is recorded on the first formal training day only for HR/HRV measures. The on-screen interface and concealed threshold line are identical; however, feedback parameters are configured to substantially weaken effective coupling between the displayed activation bar and the participant's instantaneous neural activity (T = -1; approximating p = 0.31), making stable volitional control unlikely while preserving blinding.

    Treatment: Right DLPFC fNIRS-BCI neurofeedback (sham feedback)

Questions to ask the study team

  1. How often do I need to come in, and for how long each time?
  2. Are travel costs paid?
  3. Can I keep my own doctor?
  4. What happens if I want to stop?

Contact the study team: see the registry record → Contacts and Locations

Print a page for my doctor

Data and sources

Registry record
Listed on ClinicalTrials.gov.How to verify a trial in the registry
Official title
Right Dorsolateral Prefrontal Cortex-Targeted fNIRS-BCI Closed-loop Neurofeedback for Anxiety Relief and Cardiac Autonomic Regulation in Women With Recurrent Pregnancy Loss: a Randomized, Sham-controlled Clinical Trial
Criteria questions
Built from NCT07325370, who can take part
Record updated
24 April 2026